Hide metadata

dc.date.accessioned2023-11-02T16:04:29Z
dc.date.available2023-11-02T16:04:29Z
dc.date.created2023-10-06T12:44:15Z
dc.date.issued2023
dc.identifier.citationOrstad, Silje Fløtten, Øystein Madebo, Tesfaye Gulbrandsen, Pål Strand, Roger Lindemark, Frode Fluge, Sverre Tilseth, Rune Hørgård Schaufel, Margrethe Aase . “The challenge is the complexity” – A qualitative study about decision-making in advanced lung cancer treatment. Lung Cancer. 2023, 183
dc.identifier.urihttp://hdl.handle.net/10852/105635
dc.description.abstractIntroduction The value of shared decision-making and decision aids (DA) has been well documented yet remain difficult to integrate into clinical practice. We wanted to investigate needs and challenges regarding decision-making about advanced lung cancer treatment after first-line therapy, focusing on DA applicability. Methods Qualitative data from separate, semi-structured focus groups with patients/relatives and healthcare professionals were analysed using systematic text condensation. 12 patients with incurable lung cancer, seven relatives, 12 nurses and 18 doctors were recruited from four different hospitals in Norway. Results The participants described the following needs and challenges affecting treatment decisions: 1) Continuity of clinician-patient-relationships as a basic framework for decision-making; 2) barriers to information exchange; 3) negotiation of autonomy; and 4) assessment of uncertainty and how to deal with it. Some clinicians feared DA would steal valuable time and disrupt consultations, arguing that such tools could not incorporate the complexity and uncertainty of decision-making. Patients and relatives reported a need for more information and the possibility both to decline or continue burdensome therapy. Participants welcomed interventions supporting information exchange, like communicative techniques and organizational changes ensuring continuity and more time for dialogue. Doctors called for tools decreasing uncertainty about treatment tolerance and futile therapy. Conclusion Our study suggests it is difficult to develop an applicable DA for advanced lung cancer after first-line therapy that meets the composite requirements of stakeholders. Comprehensive decision support interventions are needed to address organizational structures, communication training including scientific and existential uncertainty, and assessment of frailty and treatment toxicity.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.title“The challenge is the complexity” – A qualitative study about decision-making in advanced lung cancer treatment
dc.title.alternativeENEngelskEnglish“The challenge is the complexity” – A qualitative study about decision-making in advanced lung cancer treatment
dc.typeJournal article
dc.creator.authorOrstad, Silje
dc.creator.authorFløtten, Øystein
dc.creator.authorMadebo, Tesfaye
dc.creator.authorGulbrandsen, Pål
dc.creator.authorStrand, Roger
dc.creator.authorLindemark, Frode
dc.creator.authorFluge, Sverre
dc.creator.authorTilseth, Rune Hørgård
dc.creator.authorSchaufel, Margrethe Aase
cristin.unitcode185,53,84,0
cristin.unitnameKlinikk for helsetjenesteforskning og psykiatri
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2182434
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Lung Cancer&rft.volume=183&rft.spage=&rft.date=2023
dc.identifier.jtitleLung Cancer
dc.identifier.volume183
dc.identifier.pagecount0
dc.identifier.doihttps://doi.org/10.1016/j.lungcan.2023.107312
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0169-5002
dc.type.versionPublishedVersion
cristin.articleid107312


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International